Infliximab clearance decreases in the second and third trimesters of pregnancy in inflammatory bowel disease

BACKGROUND: Infliximab therapy during pregnancy in inflammatory bowel disease is challenged by a dilemma between maintaining adequate maternal disease control while minimizing fetal infliximab exposure. We investigated the effects of pregnancy on infliximab pharmacokinetics. METHODS: The study popul...

Descripción completa

Detalles Bibliográficos
Autores principales: Grišić, Ana‐Marija, Dorn‐Rasmussen, Maria, Ungar, Bella, Brynskov, Jørn, Ilvemark, Johan F. K. F., Bolstad, Nils, Warren, David J., Ainsworth, Mark A., Huisinga, Wilhelm, Ben‐Horin, Shomron, Kloft, Charlotte, Steenholdt, Casper
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Inflammatory Bowel Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8259366/
https://www.ncbi.nlm.nih.gov/pubmed/33079627
http://dx.doi.org/10.1177/2050640620964619

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8259366/
https://www.ncbi.nlm.nih.gov/pubmed/33079627
http://dx.doi.org/10.1177/2050640620964619

Ejemplares similares